Neogen cuts battery revenue guidance by 25-40% without explanation
FY27 battery target drops to ₹300 cr from ₹400-500 cr, while Dahej commissioning slips and Morita equity timing extends.
What's new
- Q1 consolidated revenue ₹250 cr, up 34% YoY; EBITDA ₹48.2 cr, margin 19.3%.
- Standalone/base-business guidance raised to ₹950-1,050 cr from ₹875-950 cr.
- Dahej replacement plant commercial production now targeted for Q2 FY27.
- Battery chemicals FY27 revenue guidance maintained at ₹300 cr vs prior ₹400-500 cr.
Themes from the call
Demand
Organolithium reached full utilization; battery salt revenue surged to ₹19 cr, more than half of FY26 full-year.
Margins
Base-business EBITDA margin guided at 18.0% +/- 1.5% for FY27; battery margins not quantified.
Capital allocation
Battery capex of ₹1,800 cr expected to complete by FY27-end; QIP of up to ₹600 cr to reduce debt.
Guidance watch
- Base-business FY27 revenue revised to ₹950-1,050 cr.
- Battery FY27 revenue maintained at ₹300 cr – below prior ₹400-500 cr range.
- Dahej commercial production now Q2 FY27; electrolyte commissioning H1 FY27.
- Morita's $20 mn equity contribution now expected in Q2-Q3 FY27.
- FY28 base-business revenue guided to ₹1,100-1,200 cr; battery utilization 70-80% for salt, 30-50% for electrolyte.
Risk flags
- Battery revenue guidance cut without reconciliation undermines credibility.
- Dahej commissioning slipped by a quarter with no explanation.
- Morita equity timing extended, potentially impacting battery funding.
- Battery revenue heavily dependent on customer qualifications and non-FEOC demand.
- Working capital expected to remain elevated; positive operating cash flow only by FY29.
Key quotes
-
"We had indicated that we will be having about INR 400 to INR 500 crore from the battery chemicals part of the business. No, our guidance remains the same..."
— Neogen management, Feb 2026 call -
"As we explained earlier, we are looking at 300 crores of revenue for the current year for the battery business. We currently maintain that same guidance."
— Neogen management, Jul 2026 call
The brief
Neogen Chemicals reported a strong first quarter — consolidated revenue up 34% to ₹250 crore, EBITDA margin of 19.3%, and battery salt revenue already exceeding half of last year's total. The base business looks steady: management raised standalone guidance to ₹950-1,050 crore, and organolithium ran at full capacity. But the battery chemicals story, the main reason investors own the stock, shifted materially. FY27 battery revenue guidance was quietly reset to ₹300 crore from the ₹400-500 crore range management confirmed as recently as February. No explanation was offered for the 25-40% cut. That is a credibility gap. It is compounded by two other slippages: the Dahej replacement plant's commercial production moved from June 2026 to the second quarter, and Morita's $20 million equity contribution was pushed from the first half to the second and third quarters. Both changes were disclosed without a bridge to prior commitments. On the positive side, Neogen Ionics is gaining traction — four international salt approvals, four electrolyte audits, and validation with a leading domestic cell maker. The company's battery capex of ₹1,800 crore is nearly spent, and the proposed QIP could meaningfully reduce debt. The domestic cell capacity build-out remains a powerful tailwind. But guidance is a promise. When a company cuts its flagship target by over ₹100 crore in five months without a word, the entire battery thesis becomes harder to underwrite. Neogen's battery opportunity is real. Its credibility needs repair.
Neogen's battery story looks promising, but sliding guidance and deadlines make it harder to underwrite.